ClinicalTrials.gg
Active, not recruitingNCT05656248Updated Oct 15, 2026Results posted

Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms

A Phase 2 interventional study of CPX-351 and MHA in Myeloid Neoplasm, sponsored by St. Jude Children's Research Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 1 Year to 21 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by St. Jude Children's Research Hospital · Phase 2, Interventional, and Treatment

How we know

Updated Oct 15, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
1 Year to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 53 studies testing CPX-351 in Leukemia, Myeloid, Acute — 15 open to participants now, 23 under way, 4 of them phase 3. CPX-351 · Leukemia, Myeloid, Acute.

Enrollment
32nd of 53
25 · median 30
Started
2023
with 4 others
Phase 2
25 of 53
6 open now
Primary completion
2025-08
later than 3 of 22 live
Registered
51st of 53
by date

Among the 53 studies testing CPX-351 in Leukemia, Myeloid, Acute, this one is the 32nd largest by enrollment, is one of 5 that started in 2023, is one of 25 in phase 2, reaches primary completion later than 3 of the 22 other live ones, and was the 51st registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

15 of the 53 studies testing CPX-351 in Leukemia, Myeloid, Acute are open now, in 5 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About CPX-351

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 1 Year to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing CPX-351 in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The purpose of this study is to learn the effects of treatment with an investigational drug, CPX-351 in patients with secondary myeloid neoplasms (SMNs).

Read the detailed description

Primary Objective

  • Determine the composite complete remission (CR) and complete remission with incomplete peripheral blood recovery (CRi) rates, safety and tolerability in patients under 22 years of age with SMN treated with one or two courses of CPX-351 before HSCT.

Secondary Objectives

  • Describe the toxicity profile of patients with SMN treated with one or two courses of CPX-351.
  • Estimate the 3-year overall survival of patients who received one or two courses of CPX-351 followed by HSCT.

Participants who meet the inclusion criteria and consent will receive up to 2 cycles of CPX-351 for remission induction, and then will proceed to allogeneic HSCT or other therapies as per institutional practice. If a patient attains remission and has negative MRD after the first course of CPX-351, and HSCT can occur within 3 to 4 weeks from the evaluation date of the first course, the patient can proceed to HSCT without receiving the second course of CPX-351.

03

Conditions studied

  • Myeloid Neoplasm

Keywords

  • Acute myeloid leukemia (AML)
  • Myelodysplastic syndrome (MDS)
  • Chronic myelomonocytic leukemia (CMML)]
04

Who can participate

Ages eligible
1 Year to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be ≥1 year and \< 22 years of age at the time of enrollment.
  • Patient must have one of the following diagnoses:

    • Treatment-related MDS/AML: Patients with solid organ or hematopoietic neoplasms previously treated with alkylating agents, ionizing radiation, topoisomerase inhibitors, antimetabolites, thiopurines, mycophenolate mofetil, fludarabine, and anti-tubulin agents (vincristine, vinblastine, vindesine, paclitaxel, and docetaxel usually in combination), who develop MDS, or AML are candidates for the CPXSMN protocol. If the bone marrow has between 5% and 20% blasts (higher-risk MDS), patients are discussed with the hematopoietic stem cell transplantation () team for consideration to receive chemotherapy before HSCT. If the consensus is that cytoreduction before HSCT is necessary, and the cumulative dose of doxorubicin equivalent is \< 500 mg/m2 (in cases of cardio protection) or ≤400 mg/m\^2 (cases without cardio protection), patients are eligible for the CPXSMN protocol OR
    • Secondary MDS/AML: Patients with primary MDS in transformation to AML ( cytopenia with an excess of blasts), acquired aplastic anemia evolving to AML, myeloid neoplasms arising from inherited bone marrow failure syndromes (including severe congenital neutropenia, Schwachman-Diamond syndrome, MECOM syndrome) or MDS/AML predisposition syndromes (including germline predisposition in GATA2, RUNX1, SAMD9/SAMD9L, ERCC6L2, NF1, ETV6, ANKRD26, ERCC6L2, TP53 or CEBPA genes) are eligible for the CPXSMN trial. If the bone marrow has between 5% and 20% blasts (higher-risk MDS), patients are discussed with the HSCT team for consideration to receive chemotherapy before HSCT. If the consensus is that cytoreduction before HSCT is necessary, the patients are eligible for the CPXSMN protocol.
  • Patients must have a performance status corresponding to an (ECOG) score of 0, 1 or 2. Use Karnowski for patients > 16 years of age and Lansky for patients ≤16 years of age.

    • Note: Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
  • Concomitant medications restrictions

    • See Section 4.2.5 or Appendix II (of protocol) for concomitant therapy restrictions for patients during treatment.
  • Adequate renal function defined as:

    • or radioisotope > 70 mL/min/1.73 m\^2, or
    • A serum creatinine based on age/gender as follows: Age: 1 to \< 2 years; Maximum Serum Creatinine: Male 0.6, Female 0.6; Age: 2 to \< 6 years, Maximum Serum Creatinine: Male 0.8, Female 0.8; Age: 6 to \< 10 years; Maximum Serum Creatinine: Male 1, Female 1; Age: 10 to \< 13 years; Maximum Serum Creatinine: Male 1.2, Female 1.2; Age: 13 to \< 16 years; Maximum Serum Creatinine: Male 1.5, Female 1.5; Age: ≥ 16 years; Maximum Serum Creatinine: Male 1.7, Female 1.4
  • Adequate liver function defined as (unless it is related to leukemic involvement):

    • Direct ≤1.5 x (ULN) for age and institution. At institutions that do not obtain a direct bilirubin in patients with a normal total bilirubin, a normal total bilirubin may be used as evidence that the direct bilirubin is not > 1.5 x the ULN.
    • (ALT) ≤ 3.0 x ULN for age and institution
  • Adequate cardiac function defined as:

    • Shortening fraction of ≥27% by echocardiogram, or
    • of ≥ 50% by radionuclide angiogram or echocardiogram, and
    • (QTcB) interval \< 500 msecs
  • Central nervous system function defined as:

    • Patients with seizure disorder may be enrolled if on anticonvulsants and if seizures are well controlled
    • CNS toxicity ≤ Grade 2
  • Prior therapy

    • Patients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, HSCT or radiotherapy prior to entering this study. All prior treatment-related toxicities must have resolved to ≤ Grade 2 prior to enrollment.

      1. Myelosuppressive chemotherapy: Must not have received myelosuppressive chemotherapy within 3 weeks of entry onto this study (excluding hydroxyurea). Cyto-reduction with hydroxyurea can be initiated and continued for up to 24 hours prior to the start of CPX-351.
      2. Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with , retinoids or hypomethylating agents. Note: For agents that have known adverse events occurring beyond 7 days after administration (i.e. monoclonal antibodies), this period must be extended beyond the time during which acute adverse events are known to occur.
      3. Radiation therapy (RT): ≥ 2 weeks for local palliative RT (small port); ≥ 6 months must have elapsed if prior craniospinal RT or if ≥ 50% radiation of pelvis; ≥ 6 weeks must have elapsed if other substantial BM radiation. Note: Patients must have received ≤ than 13.6 Gy prior radiation to the mediastinum. Patients with prior cumulative doxorubicin equivalent > 400 mg/m2 and prior radiation (any dose) to the mediastinum are not eligible for the protocol.
      4. Hematopoietic stem cell transplantation: No evidence of active graft vs. host disease for at least 4 weeks. For allogeneic HSCT patients, ≥ 3 months must have elapsed since HSCT.

        • Must have received no more than 1 prior autologous or allogeneic stem cell transplant.
        • Patients must be off all systemic therapy for at least 2 weeks, excluding hydrocortisone for physiologic cortisol replacement.
      5. Intrathecal cytotoxic therapy:

        • No waiting period is required for patients having received intrathecal cytarabine, methotrexate, and/or hydrocortisone.
        • At least 14 days must have elapsed since receiving liposomal cytarabine (DepoCyte) by intrathecal injection.
      6. Growth factors:

        • Patients must not have received hematopoietic growth factors for 7 days prior to CPX-351.
        • Patients must not have received pegfilgrastim for 14 days prior to CPX-351.
  • disease

    • Patients with a known history of HIV are eligible, if they meet all of the following conditions:

      • No history of HIV complications with the exception of \< 200 cells/mm\^3
      • No antiretroviral therapy with overlapping toxicity such as myelosuppression
      • CD4 count > 500 cells/mm\^3 prior to the diagnosis of relapsed AML
      • HIV viral loads below the limit of detection
      • No history of highly active antiretroviral therapy (HAART)-resistant HIV
  • Residual or relapsed solid

Patients with residual or relapsed solid malignancy (for example osteosarcoma) at the time of the diagnosis of SMN are not excluded from this trial and the treatment individualized to integrate the management of the two malignancies.

  • All patients and/or their parents or legal guardians must sign a written .

Exclusion criteria

Exclusion Criteria:

  • Patients with de novo AML (i.e., patients eligible for St. Jude or COG frontline AML trials).
  • Patients with any of the following:

    • Constitutional trisomy 21 or with constitutional mosaicism of chromosome trisomy 21
    • Patients with Fanconi anemia (DNA repair syndrome) or dyskeratosis congenita (telomeropathy)
    • Wilson disease or other copper-related metabolic disorders
    • Mixed phenotype acute leukemia
    • Philadelphia chromosome-positive myeloid neoplasms (AML or CML)
    • Acute promyelocytic leukemia (APL), or
    • Juvenile myelomonocytic leukemia (JMML) and related RASopathy disorders in chronic phase.
  • Patients who have received greater amount of doxorubicin equivalents to \<500 mg/m2 (in cases of cardio protection with dexrazoxane) or \<400mg/m2 (cases without cardio protection). For the purposes of determining eligibility for this protocol, the following cardiotoxicity multipliers will be used to determine doxorubicin equivalents:

    • Doxorubicin (reference): 1
    • Daunomycin: 0.5
    • Epirubicin: 0.5
    • Idarubicin: 5
    • Mitoxantrone: 10
  • Patients who are currently receiving another drug.
  • Patients receiving medications for treatment of left ventricular systolic dysfunction.
  • Patients with documented active, uncontrolled infection at the time of study entry.
  • Patients with known active and infections.
  • Patients with prior allergy to daunorubicin and/or cytarabine.
  • Pregnancy and breast feeding

    • Female patients who are pregnant are ineligible due to risks of fetal and teratogenic adverse events as seen in animal/human studies.
    • Lactating females who are breastfeeding an infant/child
    • Female patients of are not eligible unless a negative pregnancy test result has been obtained.
    • Sexually active patients of are not eligible unless they have agreed to use an effective method for the duration of their study participation and for at least 6 months after the last dose of protocol therapy.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    CPX-351

    Participants will receive CPX-351 for remission induction, and then will proceed to allogeneic HSCT or other therapies as per institutional practice. Intrathecal (IT) chemotherapy will be given on Day 1 of each cycle, for all participants, but may be delayed if clinically indicated. IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) according to age are all acceptable.

    Drug: CPX-351 · Drug: MHA · Procedure: Allogeneic Hematopoietic Stem Cell Transplantation

Interventions

06

What researchers measure

Primary outcomes

  1. Complete Remission (CR) and Complete Remission With Incomplete Peripheral Blood Recovery (CRi) Rate

    Proportion of participants achieving CR and proportion of participants achieving CRi by the end of one or two courses of CPX-351 Complete morphologic remission response (CR) is defined as less than 5% blasts without Auer rods by morphological evaluation of the bone marrow (M1 marrow). Patients in morphologic CR without hematological recovery (white cell blood count ≥ 1.0 x 10\^9/L, unsupported platelet count ≥ 30.0 x 10\^9/L and absolute neutrophil count ≥ 0.3 x 10\^9/L) are classified as morphological CR and incomplete recovery (CRi) of absolute neutrophil, white blood cell, and/or platelet counts.

    Time frame: Day 22 of Cycle 1 and day 22-28 of Cycle 2

  2. Tolerability Success Rate (TSR) for the First Course of Chemotherapy

    We define a tolerability success as a patient completing the first course of therapy without experiencing a grade 4 or 5 non-hematologic toxicity.

    Time frame: Adverse events will be monitored from the time of first study intervention or treatment until the completion of the first course of therapy

  3. Tolerability Success Rate (TSR) for Patients Completing the Second Course of Chemotherapy

    We define a tolerability success as a patient completing the second course of therapy without experiencing a grade 4 or 5 non-hematologic toxicity

    Time frame: Adverse events will be monitored from the time of second course of therapy until the completion of the second course of therapy.

Secondary outcomes

  1. Toxicity Profile of Patients With SMN Treated With One or Two Courses of CPX-351

    We will define categories for toxicity events and for each category we will determine the highest grade experienced by each patient. We will then report the number of patients with each grade in each category.

    Time frame: Adverse events will be monitored from the time of first study intervention or treatment until 30 days after off-therapy.

  2. Overall (OS) Survival of Patients Who Received One or Two Courses of CPX-351 Followed by HSCT

    We will use the Kaplan-Meier method to estimate overall survival. We define OS as the time elapsed from protocol enrollment to death and censor times of living patients at last follow-up.

    Time frame: 3 years from study entry

  3. Event-free Survival (EFS) of Patients Who Received One or Two Courses of CPX-351 Followed by HSCT

    We will use the Kaplan-Meier method to estimate event-free survival. We define EFS as the time elapsed from protocol enrollment to death, relapse, discontinuation of therapy due to excessive toxicity or resistant disease, or development of an additional malignancy and censor times for patients free of these events at last follow-up.

    Time frame: 3 years from study entry

  4. The Impact of Transplant on Patients Who Received One or Two Courses of CPX-351 Followed by HSCT

    To explore the impact of transplant, we will fit Cox models with transplant as a time-dependent covariate.

    Time frame: 3 years from study entry

07

Results

Posted Oct 15, 2026

Participant flow

25 patients enrolled in St. Jude between 1/17/2023 and 7/24/2025.

Participant flow — Overall Study
MilestoneCPX-351 (Vyxeos)
Started25
Completed25
Not completed0

Outcome measures

PrimaryComplete Remission (CR) and Complete Remission With Incomplete Peripheral Blood Recovery (CRi) Rate

Proportion of participants achieving CR and proportion of participants achieving CRi by the end of one or two courses of CPX-351 Complete morphologic remission response (CR) is defined as less than 5% blasts without Auer rods by morphological evaluation of the bone marrow (M1 marrow). Patients in morphologic CR without hematological recovery (white cell blood count ≥ 1.0 x 10\^9/L, unsupported platelet count ≥ 30.0 x 10\^9/L and absolute neutrophil count ≥ 0.3 x 10\^9/L) are classified as morphological CR and incomplete recovery (CRi) of absolute neutrophil, white blood cell, and/or platelet counts.

Time frame:
Day 22 of Cycle 1 and day 22-28 of Cycle 2
Reported as:
Count of participants · Participants
Complete Remission (CR) and Complete Remission With Incomplete Peripheral Blood Recovery (CRi) Rate
ParticipantsCPX-351 (Vyxeos)
CR7
CRi13
Partial Response (PR)3
No Response (NR)2
PrimaryTolerability Success Rate (TSR) for the First Course of Chemotherapy

We define a tolerability success as a patient completing the first course of therapy without experiencing a grade 4 or 5 non-hematologic toxicity.

Time frame:
Adverse events will be monitored from the time of first study intervention or treatment until the completion of the first course of therapy
Reported as:
Count of participants · Participants
Tolerability Success Rate (TSR) for the First Course of Chemotherapy
ParticipantsCPX-351 (Vyxeos)
Tolerability Success Rate (TSR) for the First Course of Chemotherapy24
PrimaryTolerability Success Rate (TSR) for Patients Completing the Second Course of Chemotherapy

We define a tolerability success as a patient completing the second course of therapy without experiencing a grade 4 or 5 non-hematologic toxicity

Time frame:
Adverse events will be monitored from the time of second course of therapy until the completion of the second course of therapy.
Reported as:
Count of participants · Participants
Tolerability Success Rate (TSR) for Patients Completing the Second Course of Chemotherapy
ParticipantsCPX-351 (Vyxeos)
Tolerability Success Rate (TSR) for Patients Completing the Second Course of Chemotherapy9
SecondaryToxicity Profile of Patients With SMN Treated With One or Two Courses of CPX-351

We will define categories for toxicity events and for each category we will determine the highest grade experienced by each patient. We will then report the number of patients with each grade in each category.

Time frame:
Adverse events will be monitored from the time of first study intervention or treatment until 30 days after off-therapy.
Reported as:
Number · participants
Toxicity Profile of Patients With SMN Treated With One or Two Courses of CPX-351
participantsGrade 2 ToxicityGrade 3 ToxicityGrade 4 Toxicity
Blood and lymphatic system disorders0180
Cardiac disorders110
Eye disorders210
Gastrointestinal disorders650
General disorders and administration site conditions521
Infections and infestations4111
Injury, poisoning and procedural complications200
Investigations111
Musculoskeletal and connective tissue disorders120
Nervous system disorders110
Respiratory, thoracic and mediastinal disorders021
Skin and subcutaneous tissue disorders910
Vascular disorders300
SecondaryOverall (OS) Survival of Patients Who Received One or Two Courses of CPX-351 Followed by HSCT

We will use the Kaplan-Meier method to estimate overall survival. We define OS as the time elapsed from protocol enrollment to death and censor times of living patients at last follow-up.

Time frame:
3 years from study entry

Results for this outcome have not been posted.

SecondaryEvent-free Survival (EFS) of Patients Who Received One or Two Courses of CPX-351 Followed by HSCT

We will use the Kaplan-Meier method to estimate event-free survival. We define EFS as the time elapsed from protocol enrollment to death, relapse, discontinuation of therapy due to excessive toxicity or resistant disease, or development of an additional malignancy and censor times for patients free of these events at last follow-up.

Time frame:
3 years from study entry

Results for this outcome have not been posted.

SecondaryThe Impact of Transplant on Patients Who Received One or Two Courses of CPX-351 Followed by HSCT

To explore the impact of transplant, we will fit Cox models with transplant as a time-dependent covariate.

Time frame:
3 years from study entry

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events will be monitored from the time of first study intervention or treatment until 30 days after off-therapy. Participants will be monitored for survival up to 3 years from enrollment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CPX-351 (Vyxeos)11/25 (44%)20/25 (80%)23/25 (92%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventCPX-351 (Vyxeos)
Febrile neutropeniaBlood and lymphatic system disorders17/25
Infections and infestations - Other, specifyInfections and infestations4/25
FeverGeneral disorders3/25
Respiratory failureRespiratory, thoracic and mediastinal disorders2/25
PapilledemaEye disorders1/25
TyphlitisGastrointestinal disorders1/25
Lung InfectionInfections and infestations1/25
Nervous system disorders - Other, specifyNervous system disorders1/25
SyncopeNervous system disorders1/25
Pleural effusionRespiratory, thoracic and mediastinal disorders1/25
Most frequent other events
Showing 10 of 16
Most frequent other events
EventCPX-351 (Vyxeos)
Infections and infestations - Other, specifyInfections and infestations6/25
Mucositis oralGastrointestinal disorders5/25
Rash maculo-papularSkin and subcutaneous tissue disorders5/25
Skin infectionInfections and infestations4/25
Skin and subcutaneous tissue disorders - Other, specifySkin and subcutaneous tissue disorders4/25
Eye disorders - Other, specifyEye disorders2/25
ConstipationGastrointestinal disorders2/25
Gastrointestinal disorders - Other, specifyGastrointestinal disorders2/25
NauseaGastrointestinal disorders2/25
TyphlitisGastrointestinal disorders2/25

Baseline characteristics

Age, Continuous
Age, Continuous(years)CPX-351 (Vyxeos)
Median11.18 (4.16 to 19.18)
Age, Continuous
Age, Continuous(years)CPX-351 (Vyxeos)
Mean12.16 ± 4.65
Sex: Female, Male
Sex: Female, Male(Participants)CPX-351 (Vyxeos)
Female9
Male16
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)CPX-351 (Vyxeos)
Asian1
Black3
White14
Multiple Race (NOS)2
Pacific Islander1
UnKnown4
08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Individual participant de-identified datasets containing the variables analyzed in the published article will be made available (related to the study primary or secondary objectives contained in the publication). Supporting documents such as the protocol, statistical analyses plan, and informed consent are available through the CTG website for the specific study. Data used to generate the published article will be made available at the time of article publication. Investigators who seek access to individual level de-identified data will contact the computing team in the Department of Biostatistics (ClinTrialDataRequest@stjude.org) who will respond to the data request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be made available at the time of article publication.

Access criteria: Data will be provided to researchers following a formal request with the following information: full name of requestor, affiliation, data set requested, and timing of when data is needed. As an informational point, the lead statistician and study principal investigator will be informed that primary results datasets have been requested.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Aug 2025, 31 months.

Results were first posted in Oct 2026, 1 year 1 month after primary completion.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's 31 months is below that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2022
First posted
Dec 19, 2022
StartActual
Jan 17, 2023
Primary completionActual
Aug 28, 2025
CompletionEst.
Aug 2028
Results first posted
Oct 15, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 15, 2026
Primary outcomes
1 edited, 2 added, 2 removed
What changed in the outcomes
  • EditedComplete remission with incomplete peripheral blood recoveryRemission (CR) and Complete Remission With Incomplete Peripheral Blood Recovery (CRi) rates after one or two courses of CPX-351RateTime frame: After one or 2 course of CPX-351, no later than day 42 from the start of each course of chemotherapy → Day 22 of Cycle 1 and day 22-28 of Cycle 2
  • AddedTolerability Success Rate (TSR) for the First Course of ChemotherapyTime frame: Adverse events will be monitored from the time of first study intervention or treatment until the completion of the first course of therapy
  • AddedTolerability Success Rate (TSR) for Patients Completing the Second Course of ChemotherapyTime frame: Adverse events will be monitored from the time of second course of therapy until the completion of the second course of therapy.
  • RemovedComposite complete remission (CR) rates after one or two courses of CPX-351Time frame: After one or 2 course of CPX-351, no later than day 42 from the start of each course of chemotherapy
  • RemovedSafety and tolerability in patients under 22 years of age with SMN treated with one or two courses of CPX-351 before HSCTTime frame: After one or 2 course of CPX-351, prior to hematopoietic stem cell transplantation (HSCT), three to four weeks from the hematologic recovery
Oct 15, 2026
Documents
Secondary outcomes
4 edited
What changed in the outcomes
  • EditedToxicity profileProfile of patients withPatients With SMN treated with oneTreated With One or two coursesTwo Courses of CPX-351Time frame: 30 days after completion of one or two courses of chemotherapy → Adverse events will be monitored from the time of first study intervention or treatment until 30 days after off-therapy.
  • EditedOverall (OS) survivalSurvival of patients who received onePatients Who Received One or two coursesTwo Courses of CPX-351 followedFollowed by HSCTTime frame: 3 years from study entry
  • EditedEvent-free survivalSurvival (EFS) of patients who received onePatients Who Received One or two coursesTwo Courses of CPX-351 followedFollowed by HSCTTime frame: 3 years from study entry
  • EditedThe impactImpact of transplantTransplant on patients who received onePatients Who Received One or two coursesTwo Courses of CPX-351 followedFollowed by HSCTTime frame: 3 years from study entry
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Results posted
    Primary outcomes 1 edited, 2 added, 2 removed
    What changed in the outcomes
    • EditedComplete remission with incomplete peripheral blood recoveryRemission (CR) and Complete Remission With Incomplete Peripheral Blood Recovery (CRi) rates after one or two courses of CPX-351RateTime frame: After one or 2 course of CPX-351, no later than day 42 from the start of each course of chemotherapy → Day 22 of Cycle 1 and day 22-28 of Cycle 2
    • AddedTolerability Success Rate (TSR) for the First Course of ChemotherapyTime frame: Adverse events will be monitored from the time of first study intervention or treatment until the completion of the first course of therapy
    • AddedTolerability Success Rate (TSR) for Patients Completing the Second Course of ChemotherapyTime frame: Adverse events will be monitored from the time of second course of therapy until the completion of the second course of therapy.
    • RemovedComposite complete remission (CR) rates after one or two courses of CPX-351Time frame: After one or 2 course of CPX-351, no later than day 42 from the start of each course of chemotherapy
    • RemovedSafety and tolerability in patients under 22 years of age with SMN treated with one or two courses of CPX-351 before HSCTTime frame: After one or 2 course of CPX-351, prior to hematopoietic stem cell transplantation (HSCT), three to four weeks from the hematologic recovery
    Secondary outcomes 4 edited
    What changed in the outcomes
    • EditedToxicity profileProfile of patients withPatients With SMN treated with oneTreated With One or two coursesTwo Courses of CPX-351Time frame: 30 days after completion of one or two courses of chemotherapy → Adverse events will be monitored from the time of first study intervention or treatment until 30 days after off-therapy.
    • EditedOverall (OS) survivalSurvival of patients who received onePatients Who Received One or two coursesTwo Courses of CPX-351 followedFollowed by HSCTTime frame: 3 years from study entry
    • EditedEvent-free survivalSurvival (EFS) of patients who received onePatients Who Received One or two coursesTwo Courses of CPX-351 followedFollowed by HSCTTime frame: 3 years from study entry
    • EditedThe impactImpact of transplantTransplant on patients who received onePatients Who Received One or two coursesTwo Courses of CPX-351 followedFollowed by HSCTTime frame: 3 years from study entry
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05656248
Responsible party
Sponsor
First posted
Dec 19, 2022
Start date
Jan 17, 2023
Primary completion
Aug 28, 2025
Completion
Aug 2028 (estimated)
Results posted
Oct 15, 2026
Last update
Oct 15, 2026

Study contacts

Raul C. Ribeiro, MD
principal investigator · St. Jude Children's Research Hospital
Marcin Wlodarski, MD, PhD
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CPX-351

Start the discussion